Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults
NCT00098098
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
RECOMBINANT BOTULINUM VACCINE A/B
Interventions
BIOLOGICAL:
rBV A/B
Sponsor
DynPort Vaccine Company LLC, A GDIT Company